Core Viewpoint - Crystal Tech Holdings (02228) reported a significant turnaround in its financial performance for the six months ending June 30, 2025, with a revenue increase of 403.83% year-on-year, reaching 517 million RMB, and a shift from a loss of 1.237 billion RMB to a profit of 82.795 million RMB for shareholders [1] Financial Performance - Revenue for the drug discovery solutions business surged by 615.2%, from 60.9 million RMB for the six months ending June 30, 2024, to 435 million RMB for the same period in 2025, primarily driven by a major collaboration with DoveTree Medicines LLC [1] - The company achieved a milestone in its collaboration with DoveTree, receiving an initial payment of 51 million USD [1] - The antibody business also demonstrated strong revenue growth during the reporting period [1] Cash Position and Profitability - As of the end of the reporting period, the company had a cash balance of 5.308 billion RMB, indicating a solid financial position [1] - Monthly average cash consumption decreased by 20.0% to 49.7 million RMB during the first half of the year [1] - The adjusted net profit for the first half of the year was 142 million RMB, marking the first time the company achieved half-year profitability, signifying a new growth phase for the company [1]
晶泰控股(02228)发布中期业绩 股东应占溢利8279.5万元 同比扭亏为盈